Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
May 20, 2025TORONTO, ON – May 20, 2025 – Apotex Inc. ("Apotex"), the Canadian-based global health company, today published its 2024 Sustainability Report, showcasing its ongoing commitment to sustainable, responsible business practices and its global impact.
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
Key achievements include:
- Sourcing 81% of global electricity consumption from renewable or low-carbon sources in 2024 and significant reductions in Scope 1 and 2 emissions through the implementation of energy-efficient technologies across our facilities
- More than $1.5 million in essential products donated to vulnerable populations in 2024, and the establishment of the Apotex Global Health Access Fund, which provides long-term funding to support maternal health initiatives in Canada, the United States, Mexico, and India
- Enhancement of Apotex's Global Risk Management Program and strengthening the Global Business Ethics and Compliance Program to further enhance transparency and accountability
- Hiring a new Head of Sustainability to further advance Apotex's enterprise-wise ESG strategy
Apotex has also made strides in waste management, achieving notable reductions in waste generation by applying green chemistry principles and innovative recycling programs, and aims to continue implementing energy-efficient technologies and renewable energy solutions to further reduce its environmental footprint.
Learn more about sustainability at Apotex.
About Apotex
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide, with a broad portfolio of generic, biosimilar, innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at www.apotex.com.
Media Contact: media@apotex.com
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
May 25, 2025
Apotex launches nilotinib capsules, the first generic version of Tasigna®¹ in the United States, with 180 days of exclusivity
Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
-
May 9, 2025
Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States
Weston, Florida (May 09, 2025) – Apotex Corp. today launched IVRA™ (Melphalan) hydrochloride injection 90mg/ml multidose vial ("IVRA"), first ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States.